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Abstract 
    Currently, major categories of antihypertensive agents include diuretics, beta-blockers, calcium channel 
blockers (CCBs), renin-angiotensin system (RAS) inhibitors [angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARB)]. Among them, RAS (ACE inhibitors and ARB) would be recommended to be 
a first-line treatment when providing antihypertensive agents for hypertensive patients with diabetes, 
cardiovascular disease, and impaired renal function. Randomized controlled trials (RCT) of RAS inhibitors 
compared with other antihypertensive showed a rather lower relative risk (RR). They are all-cause death (RR - 
0.95), cardiovascular death (RR - 0.84), incidence of cardiovascular disease (RR - 0.93), and incidence of renal 
dysfunction (RR - 0.91). 
 
    Hypertension is widely prevalent worldwide. It has 
been an important disease to cause death and 
disability from stroke and cardiovascular disease 
(CVD) worldwide [1]. According to the 2017 American 
College of Cardiology (ACC)/American Heart 
Association (AHA) clinical practice guidelines on 
hypertension, patient number with diagnosed and 
undetected hypertension is markedly increasing [2]. 
Results of the SPRINT (Systolic Blood Pressure 
Intervention Trial) data showed that intensively 
controlled blood pressure could significantly reduce 
mortality and CVD events [3]. There has been a report 
of the National Heart, Lung, and Blood Institute 
Working Group on Hypertension [4].  
 
    Consequently, adequate treatment for hypertension 
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can reduce cardiovascular mortality [5]. Currently, 
major categories of antihypertensive agents include 
diuretics, beta-blockers, calcium channel blockers 
(CCBs), renin-angiotensin system (RAS) inhibitors 
[angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARB)].  
 
    For initial therapy for hypertension, beta-blockers 
have been prevalent since the 1960s. Due to a 
systematic review, beta-blockers showed significantly 
reduced stroke and cardiovascular events. However, 
they did not reduce congestive heart disease and all-
cause mortality [6]. Among them, the clinical effect of 
beta-blockers was less than low-dose thiazides, ACE 
inhibitors, and CCB [6]. According to the Cochrane 
study, dual alpha and beta-blockers lowered BP for 6 / 
4mmHg on average. Also, this effect was less than that 
of beta1-selective blockers [7]. Another Cochrane 
review revealed that beta1-selective blockers have a 
stronger lowering effect of 10 / 8mmHg. Furthermore, 
beta1-selective blockers reduced blood pressure (BP) 
to a greater degree in comparison with dual alpha and 
beta-blockers [8]. 
 
    For general information on beta-blockers, 
propranolol has an affinity for beta1 and beta2 
receptors as a non-selective beta-blocker [5]. Among 
beta-blockers, the most commonly used agent has 
been atenolol. Atenolol and bisoprolol preferentially 
interact with beta1 more than beta2 receptors as 
selective beta-blockers. Carvedilol exhibits affinity for 
beta1 and alpha receptors as dual alpha and beta-
blocker [5]. There was a report comparing the effect 
of carvedilol and bisoprolol for patients with heart 
failure with reduced ejection fraction (HFrEF) [9]. As 
a result, the prescription of beta-blockers reduced all-
cause mortality (HR 0.59), and two agents had 
comparable effects.  
 
    Secondly, diabetes has been also crucial disease in 
the world, frequently associated with high blood 
pressure. For patients with type1 and 2 diabetes 
mellitus (T1DM and T2DM), hypertension has been a 
very common complication [10,11]. To continue good 
BP control can bring effect for reducing the 
macrovascular and microvascular complications 
[12,13]. According to the guideline of the United States 
and Europe, the degree of reducing BP would become 
the main determinant of lowering cardiovascular risk 
in comparison with the administration of [2,14].  
 
    Among their guidelines, some antihypertensive 
agents have been considered to decrease 
cardiovascular events for diabetic patients, including 
thiazide-like diuretics, CCBs, ACE inhibitors, ARBs. 
ACE inhibitors and ARBs belong to the group of RAS 
inhibitors, which have been provided as first-line 
therapy for hypertensive diabetic patients. 
 
    There was a meta-analysis of randomized 
controlled trials to study the efficacy among RAS 
inhibitors and another antihypertensive [15]. From a 
total 16 trials with 35,052 patients, the result showed 
a rather lower relative risk (RR). They are all-cause 
death (RR 0.95), cardiovascular death (RR 0.84), the 
incidence of cardiovascular disease (RR 0.93), and 
incidence of renal dysfunction (RR 0.91), while there 
were no significant differences [15].   
 
    RAS inhibitors mainly include ACE inhibitors and 
ARBs and show the beneficial effect of reducing 
urinary albumin [16]. The presence of albuminuria 
has been estimated to be a risk factor for 
cardiovascular events [17]. Then, RAS inhibitors have 
been primarily the first-line antihypertensive for 
diabetic patients, because they have also improved 
insulin-resistant effect and Renoprotective effect [18]. 
From mentioned above, RAS inhibitors are 
recommended to provide patients who are diabetic 
hypertensive, associated with some renal function 
impairment such as proteinuria or microalbuminuria.  
 
    For hypertensive diabetic patients, there are 
reports of a meta-analysis of trials that compare RAS 
inhibitors and other category agents [19,20]. From the 
results, RAS inhibitors showed no better than other 
agents as a first-line antihypertensive agent for 
several markers. They include the degree of reducing 
cardiovascular death, all-cause death, the incidence of 
renal dysfunction and the incidence of cardiovascular 
disease. Their summarized effects were suggested to 
show lower risks, whereas statistically significant 
difference was not found [17,20]. These results were 
consistent with those of relevant major known 
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guidelines [2,13,14]. 
 
    There are some guidelines for adequate treatment 
for hypertensive patients with diabetes. Among them, 
RAS inhibitors have been recommended as first-line 
treatment [17,18]. From a statistic point of view, some 
cases show significant differences in certain research 
protocols. The probable factors would be in the 
following: i) comparison of RAS inhibitors with CCBs 
or with beta-blockers or diuretics, ii) proposed target 
blood pressure, iii) enough effect of assigned agents, 
iv) follow-up period of the protocol in the trials, v) 
included or excluded for patients with impaired renal 
function and vi) positive or negative for the history of 
the cardiovascular accident. Generally, the 
recommendation was almost based on the expected 
protective efficacy of RAS inhibitors over placebo 
medicine from diabetic nephropathy [17,18].  
 
    When a multidrug regimen can be used to achieve 
for the target BP, the administration of a RAS 
inhibitor to the protocol may be successful [20]. 
According to the research protocol, a protective effect 
for nephropathy of each agent would be considered 
[20,21]. Recently, the updated guidelines by the 
European Society of Cardiology and European Society 
of Hypertension (ESC/ESH) 2018 have included such 
clinical judgments [21].  
 
    For hypertensive patients with diabetes and 
albuminuria, the guidelines or statements showed the 
recommendation including ACE inhibitors or ARBs for 
the initial treatment of risk reduction against the 
progression of renal disease [21]. There has been 
some evidence for the judgment by some guidelines 
such as the 2017 American Hospital 
Association/American College of Cardiology 
Guidelines. However, the relevant recommendation 
has been as Class IIb, which means a weak degree 
[2,21]. 
 
    In summary, recent topics concerning the 
treatment for hypertensive patients with diabetes and 
its complications would be described. As an 
antihypertensive agent, RAS agents such as ACE 
inhibitors and ARBs have been recommended for 
expecting the preventive effects. This article may 
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